Hossam El Benawi on Comparison of DOACs and VKAs in the Treatment of Left Ventricular Thrombi
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:
”The optimal duration of anticoagulation for left ventricular thrombus (LVT) remains unclear.
The 2022 AHA guidelines recommend treatment with a VKA or DOAC for at least 3–6 months, with longer therapy considered if needed.
However, evidence is limited.
Key questions include:
- What is the ideal duration of anticoagulation for LVT resolution?
- Do DOACs and VKAs differ in their effectiveness at resolving LVT?
Insights from our analysis (Mayo Clinic’s Multi-site LVT Study):
At 6 months post-LVT diagnosis, LVT resolution: 61% of patients treated with DOAC vs 61% treated with VKA (p = 1.0). Figure A.
20% of patients on DOAC required longer than 6 months for LVT resolution, compared to 26% of those on VKA ( p=0.31). Figure B.
The median time to LVT resolution was similar (DOAC: 96 days [IQR:67-180] and VKA: 102 days [IQR:68 -199], p = 0.22)
Despite anticoagulation therapy, Persistent LVT was 19.6% of the DOAC group and 13% of the VKA group (p=0.23). Figure B.
These findings suggest that a subset of LVT patients may need prolonged therapy (>6 months), underscoring the importance of tailored treatment strategies based on individual patient clinical characteristics.”
Read the full article here.
Article: Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi, A Retrospective Cohort Study
Authors: Hossam El Benawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 24, 2025, 10:25Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
-
Nov 24, 2025, 10:06Amirpasha Moetazedian Invites a PHD Student to His Lab to Explore Sustainable Artificial Blood Vessels
-
Nov 24, 2025, 09:41Kamran Hajiyev Reflects on A Week of Innovation, Collaboration, and Scientific Exchange at SVIN 2025
-
Nov 24, 2025, 02:55Do You Know Why Clot Contracts? Marin Pavlov Reflects on Expert PE Conference 2025
-
Nov 24, 2025, 01:39Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
-
Nov 24, 2025, 01:10Swarsat K Nath on HemeNext 2025: AI is Real, Measurable, and Already Changing Lives
-
Nov 23, 2025, 15:15Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
-
Nov 23, 2025, 14:57Jesse Landry on SeraGene Therapeutics: Rewriting the Rules of Blood and Bleeding Disorders
-
Nov 23, 2025, 14:49Reza Shojaei: What Truly Motivates Donors And What Keeps Them Coming Back?
